{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:34:58Z","timestamp":1792226098520,"version":"4.4.0"},"reference-count":79,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vifor Pharma Deutschland GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>The association between vitamin D deficiency and especially critical shortage of active vitamin D (1,25-dihydroxyvitamin D, calcitriol) with the development of secondary hyperparathyroidism (sHPT) is a well-known fact in patients with chronic kidney disease (CKD). The association between sHPT and important clinical outcomes, such as kidney disease progression, fractures, cardiovascular events, and mortality, has turned the prevention and the control of HPT into a core issue of patients with CKD and on dialysis. However, vitamin D therapy entails the risk of unwanted side effects, such as hypercalcemia and hyperphosphatemia. This review summarizes the developments of vitamin D therapies in CKD patients of the last decades, from calcitriol substitution to extended-release calcifediol. In view of the study situation for vitamin D insufficiency and sHPT in CKD patients, we conclude that the nephrology community has to solve three core issues: (1) What is the optimal parathyroid hormone (PTH) target level for CKD and dialysis patients? (2) What is the optimal vitamin D level to support optimal PTH titration? (3) How can sHPT treatment support reduction in the occurrence of hard renal and cardiovascular events in CKD and dialysis patients?<\/jats:p>","DOI":"10.3390\/nu14153009","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T01:42:13Z","timestamp":1658713333000},"page":"3009","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future"],"prefix":"10.3390","volume":"14","author":[{"given":"Vincent","family":"Brandenburg","sequence":"first","affiliation":[{"name":"Department of Cardiology and Nephrology, Rhein-Maas-Klinikum W\u00fcrselen, Mauerfeldchen 25, 52146 W\u00fcrselen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ketteler","sequence":"additional","affiliation":[{"name":"Departmentof General Internal Medicine and Nephrology, Robert-Bosch Hospital, Auerbachstra\u00dfe 110, 70376 Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Franca Gois, P.H., Wolley, M., Ranganathan, D., and Seguro, A.C. (2018). Vitamin D Deficiency in Chronic Kidney Disease: Recent Evidence and Controversies. Int. J. Environ. Res. Public Health, 15.","DOI":"10.20944\/preprints201807.0320.v1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: Report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"98","author":"Caramori","year":"2020","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2019.07.022","article-title":"Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"75","author":"Isakova","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.5414\/CP203737","article-title":"Prevalence and influencing factors of vitamin D deficiency in chronic kidney disease: A cross-sectional study","volume":"58","author":"Li","year":"2020","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_6","first-page":"220","article-title":"Alta prevalencia de deficiencia de vitamina D en ni\u00f1os con enfermedad renal cr\u00f3nica y trasplante renal","volume":"115","author":"Coccia","year":"2017","journal-title":"Arch. Argent. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.ajkd.2011.12.035","article-title":"Ergocalciferol and cholecalciferol in CKD","volume":"60","author":"Nigwekar","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bonekey.2013.232","article-title":"Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD)","volume":"3","author":"Nigwekar","year":"2014","journal-title":"Bonekey Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/nyas.13464","article-title":"Chronic kidney disease and vitamin D metabolism in human bone marrow-derived MSCs","volume":"1402","author":"Zhou","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Christensen, M.H.E., Apalset, E.M., Nordb\u00f8, Y., Varhaug, J.E., Mellgren, G., and Lien, E.A. (2013). 1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism Apa1 influence bone mineral density in primary hyperparathyroidism. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056019"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000514286","article-title":"Pathophysiological Implication of Vitamin D in Diabetic Kidney Disease","volume":"46","year":"2021","journal-title":"Kidney Blood Press. Res."},{"key":"ref_13","first-page":"37","article-title":"Secondary-Hyperparathyroidism-in-Non-dialysis-Chronic-Kidney-Disease","volume":"9","author":"Germain","year":"2021","journal-title":"EMJ Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40348-021-00123-x","article-title":"How FGF23 shapes multiple organs in chronic kidney disease","volume":"8","author":"Haffner","year":"2021","journal-title":"Mol. Cell. Pediatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","article-title":"Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion","volume":"10","author":"Centeno","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mace, M.L., Olgaard, K., and Lewin, E. (2020). New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228810"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bone.2017.01.023","article-title":"The chronic kidney disease\u2014Mineral bone disorder (CKD-MBD): Advances in pathophysiology","volume":"100","author":"Hruska","year":"2017","journal-title":"Bone"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"KDIGO (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","article-title":"Chronic kidney disease-mineral-bone disorder: A new paradigm","volume":"14","author":"Moe","year":"2007","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"F253","DOI":"10.1152\/ajprenal.00302.2004","article-title":"The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism","volume":"288","author":"Rodriguez","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/ndt\/gfm177","article-title":"Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies","volume":"22","author":"Drueke","year":"2007","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2016.11.012","article-title":"Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho","volume":"100","author":"Yamada","year":"2017","journal-title":"Bone"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1161\/01.HYP.0000219635.51844.da","article-title":"Calcification and cardiovascular health: New insights into an old phenomenon","volume":"47","author":"Ketteler","year":"2006","journal-title":"Hypertension"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2215\/CJN.07450714","article-title":"Vascular calcification in patients with nondialysis CKD over 3 years","volume":"10","author":"Molina","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000072552","article-title":"Pathogenesis and treatment of renal osteodystrophy","volume":"21","author":"Slatopolsky","year":"2003","journal-title":"Blood Purif."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00223-020-00779-z","article-title":"Bone Fragility Fractures in CKD Patients","volume":"108","author":"Pimentel","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/ki.2013.547","article-title":"The three-year incidence of fracture in chronic kidney disease","volume":"86","author":"Naylor","year":"2014","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00198-019-05033-3","article-title":"Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease","volume":"30","author":"Geng","year":"2019","journal-title":"Osteoporos Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"c159","DOI":"10.1159\/000099006","article-title":"Secondary hyperparathyroidism is associated with higher cost of care among chronic kidney disease patients with cardiovascular comorbidities","volume":"105","author":"Khan","year":"2007","journal-title":"Nephron Clin. Pract."},{"key":"ref_30","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 113, S1\u2013S130."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1136\/bmj.282.6280.1919","article-title":"Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis","volume":"282","author":"Memmos","year":"1981","journal-title":"Br. Med. J. (Clin. Res. Ed)"},{"key":"ref_32","first-page":"287","article-title":"Controlled trial of calcitriol in the prevention of bone disease in haemodialysed patients","volume":"19","author":"Sharman","year":"1983","journal-title":"Proc. Eur. Dial. Transpl. Assoc."},{"key":"ref_33","first-page":"102","article-title":"Evolution of renal osteodystrophy: Correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol","volume":"2","author":"Bordier","year":"1975","journal-title":"Kidney Int. Suppl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/978-1-4613-4217-5_57","article-title":"Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure","volume":"81","author":"Letteri","year":"1977","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2215\/CJN.02140309","article-title":"Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease","volume":"4","author":"Kovesdy","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/ndt\/gfw080","article-title":"Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease","volume":"31","author":"Agarwal","year":"2016","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/ckj\/sfab035","article-title":"Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: A meta-analysis","volume":"14","author":"Bover","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJM198908033210509","article-title":"Renal osteodystrophy","volume":"321","author":"Malluche","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cpt1978235515","article-title":"Calcitriol in dialysis patients","volume":"23","author":"Maxwell","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/BF03044785","article-title":"Orale Calcitriolstosstherapie bei H\u00e4modialysepatienten. Auswirkungen auf die Histomorphometrie des Knochens bei renalem Hyperparathyreoidismus","volume":"92","author":"Sperschneider","year":"1997","journal-title":"Med. Klin."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1093\/ckj\/sfab091","article-title":"Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: A systematic review and meta-analysis","volume":"14","author":"Cozzolino","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/17446651.2017.1347501","article-title":"Extended-release calcifediol for secondary hyperparathyroidism in stage 3\u20134 chronic kidney disease","volume":"12","author":"Sprague","year":"2017","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_43","unstructured":"Lung, B.E., Mowery, M.L., and Komatsu, D.E.E. (2022). StatPearls: Calcitriol, StatPearls Publishing LLC."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000518110","article-title":"Small Intestinal Phosphate Absorption: Novel Therapeutic Implications","volume":"52","author":"Yee","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_45","first-page":"1478","article-title":"Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis","volume":"342","author":"Goldin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_46","first-page":"167","article-title":"Cardiovascular disease in uremic patients on hemodialysis","volume":"2","author":"Lazarus","year":"1975","journal-title":"Kidney Int. Suppl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1053\/ajkd.2001.28113","article-title":"Secondary hyperparathyroidism in chronic renal failure: Pathogenic and clinical aspects","volume":"38","author":"Llach","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(01)01781-8","article-title":"Cardiac calcification in adult hemodialysis patients","volume":"39","author":"Raggi","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","first-page":"95","article-title":"High doses of intravenous calcitriol in the treatment of severe secondary hyperparathyroidism","volume":"17","author":"Morosetti","year":"2004","journal-title":"J. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrneph.2011.91","article-title":"Mechanisms and treatment of extraosseous calcification in chronic kidney disease","volume":"7","author":"Ketteler","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1172\/JCI17202","article-title":"The serum protein \u03b12\u2013Heremans-Schmid glycoprotein\/fetuin-A is a systemically acting inhibitor of ectopic calcification","volume":"112","author":"Heiss","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.mseb.2011.06.011","article-title":"Vascular calcification: Inducers and inhibitors","volume":"176","author":"Lee","year":"2011","journal-title":"Mater. Sci. Eng. B"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1525-139X.2005.18407.x","article-title":"The role of vitamin D in vascular calcification in chronic kidney disease","volume":"18","author":"Wolisi","year":"2005","journal-title":"Semin. Dial."},{"key":"ref_54","first-page":"135","article-title":"Adynamic bone disease-bone and beyond","volume":"1","author":"Brandenburg","year":"2008","journal-title":"NDT Plus"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5414\/CNP71593","article-title":"Paricalcitol and outcome: A manual on how a vitamin D receptor activator (VDRA) can help us to get down the \u201cU\u201d","volume":"71","author":"Cozzolino","year":"2009","journal-title":"Clin. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Pereira","year":"2011","journal-title":"Kidney Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Mannstadt","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000072822","article-title":"The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients","volume":"23","author":"Chertow","year":"2003","journal-title":"Am. J. Nephrol."},{"key":"ref_61","first-page":"765","article-title":"Clinical counterpoint: Vitamin D: New actions, new analogs, new therapeutic potential","volume":"13","author":"Bikle","year":"1992","journal-title":"Endocr. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2","volume":"32","author":"Llach","year":"1998","journal-title":"Am. J. Kidney Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2014the OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jsbmb.2014.11.022","article-title":"Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation","volume":"148","author":"Petkovich","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000450766","article-title":"Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease","volume":"44","author":"Sprague","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1159\/000518545","article-title":"Real-World Assessment: Clinical Effectiveness and Safety of Extended-Release Calcifediol","volume":"52","author":"Fadda","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","article-title":"Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study","volume":"30","author":"Dionisi","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2215\/CJN.04530418","article-title":"Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis","volume":"14","author":"Petrykiv","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"101175","DOI":"10.1016\/j.bonr.2022.101175","article-title":"Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes\u2014Data from a randomized, placebo-controlled study","volume":"16","author":"Rau","year":"2022","journal-title":"Bone Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/HJH.0000000000000927","article-title":"Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: Results from the EPATH randomized, placebo-controlled trial","volume":"34","author":"Tomaschitz","year":"2016","journal-title":"J. Hypertens."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7326\/M17-2640","article-title":"Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update","volume":"168","author":"Ketteler","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.ajkd.2018.03.026","article-title":"Serum Calcitriol Concentrations and Kidney Function Decline, Heart Failure, and Mortality in Elderly Community-Living Adults: The Health, Aging, and Body Composition Study","volume":"72","author":"Selamet","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1681\/ASN.2020050598","article-title":"Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients","volume":"32","author":"Isaka","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/CIRCRESAHA.120.318556","article-title":"Randomized trial of etelcalcetide for cardiac hypertrophy in hemodialysis","volume":"128","author":"Kammer","year":"2021","journal-title":"Circ. Res."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/14\/15\/3009\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:54:49Z","timestamp":1760140489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/14\/15\/3009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":79,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["nu14153009"],"URL":"https:\/\/doi.org\/10.3390\/nu14153009","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]}}}